Objective-Pulmonary arterial hypertension is a progressive pulmonary vascular disorder with high morbidity and mortality. Compelling evidence suggests that receptor tyrosine kinases, such as platelet-derived growth factor (PDGF) are closely involved in the pathogenesis of pulmonary arterial hypertension. We investigated the effects of 2 novel PDGF inhibitors, nilotinib/AMN107 (Abl kinases/PDGF receptor inhibitor) and dasatinib/BMS-354825 (Abl kinases/PDGF receptor/Src inhibitor), on the proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) and on the hemodynamics and pulmonary vascular remodeling in experimental pulmonary hypertension, and determined the expression and regulation of Src family kinases. Methods and Results-Human PASMCs were stimulated by PDGF alone or multiple growth factors to induce proliferation and migration in vitro. Dasatinib (0.03 mol/L), nilotinib (0.3 mol/L), and imatinib (1 mol/L) potently inhibited PDGF-induced signal transducer and activator of transcription 3 and Akt phosphorylation. All 3 inhibitors decreased PDGF-induced proliferation, cell cycle gene regulation, and migration. In contrast, only dasatinib inhibited multiple growth factor-induced PASMC proliferation, and this was associated with the inhibition of Src phosphorylation. Combination of specific Src inhibitors (phosphoprotein phosphatase 1, phosphoprotein phosphatase 2) with either imatinib or nilotinib reduced multiple growth factor-induced proliferation to a similar extent as dasatinib. Importantly, Src phosphorylation increased in pulmonary arterial hypertension PASMCs compared with control PASMCs. Finally, in vivo dasatinib (15 mg/kg per body weight) treatment caused a complete reversal of pulmonary vascular remodeling and achieved similar effectiveness as imatinib (100 mg/kg per body weight) in both monocrotaline-and hypoxia-induced pulmonary hypertension models. 
integrative Physiology/experimental Medicine P ulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disorder with high morbidity and mortality. 1 Current therapeutic approaches for the treatment of PAH mainly provide symptomatic relief, as well as some improvement in prognosis. Pathological changes observed in vascular remodeling include endothelial injury, proliferation, and migration of pulmonary arterial smooth muscle cells (PASMCs), causing medial hypertrophy of the intraacinar muscular resistance vessels, muscularization of the normally nonmuscular precapillary arterioles, and an increase in connective tissue deposition in the medial layer. 2 Over recent years, considerable evidence has been accumulated suggesting the involvement of receptor tyrosine kinases (RTK), such as the platelet-derived growth factor (PDGF) receptor, in the pathogenesis of pulmonary vascular remodeling. A complete analysis of the pathogenic role of PDGF in PAH demonstrated an increased expression of PDGF ligands and receptors (PDGFR) in pulmonary arteries of idiopathic PAH lungs. 3, 4 In addition, PDGF was shown to primarily contribute to the proliferative and migratory phenotype of PASMCs. 5 Administration of imatinib, a small molecular inhibitor that inhibits PDGFR/Abl and c-Kit, 6 was shown to reverse vascular remodeling in severe experimental role of src Tyrosine Kinases in experimental Pulmonary Hypertension pulmonary hypertension (PH). 5 Patients with severe PAH, who failed to be stabilized even by extensive combined application of approved PAH therapies, were beneficially influenced by compassionate use of imatinib as rescue therapy. 7, 8 Inhibition of PDGFR by imatinib, however, requires micromolar concentrations in cell-based assays. 9, 10 Similarly, higher concentrations are required to achieve reverse remodeling effects in preclinical models of PH. 5 This prompted us to search for other tyrosine kinase inhibitors that can potently inhibit PDGFR/Abl tyrosine kinases. In addition, activation of epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin growth factor (IGF), and insulin recep tors was shown to contribute to PASMC proliferative responses. 11 These findings suggest that inhibitors that can target a common downstream signaling molecule of RTKs can be of potential therapeutic value.
Nilotinib (AMN107) and dasatinib (BMS-354825) are 2 novel inhibitors of PDGFR/Abl and c-Kit (so-called second-generation RTK inhibitor), which have shown higher potency compared with imatinib in in vitro kinase assays. 12, 13 Importantly, dasatinib apart from PDGFR/Abl and c-Kit also inhibits the structurally related Src family kinases (SFKs).
14 These 2 compounds are in clinical development for oncology indications. 13 SFKs are the largest subfamily of non-RTKs consisting of 9 kinases, namely Src (c-Src), Yes, Fyn, Blk, Lyn, Hck, Yrs, Lck, Fgr, which share similar structures and function. 15 SFKs play an important role in regulating signals from many RTKs and have evolved many ingenious molecular strategies to couple receptors with the cytoplasmic signaling machinery. Thus SFKs can promote mitogenic signaling from RTKs in many ways, including initiation of signaling pathways required for DNA synthesis, control of receptor turnover, differentiation, actin cytoskeleton rearrangements, motility, and survival. 16, 17 However, contribution of SFKs to vascular remodeling and to the pathogenesis of PAH has not been explored yet. Because dasatinib inhibits SFKs, it would be interesting to know how dasatinib regulates SFKs in PAH and in turn pulmonary vascular remodeling.
We sought to (1) determine the influence of nilotinib and dasatinib on PDGF signaling and PDGF-stimulated migration and proliferation of PASMCs compared with imatinib; (2) study whether imatinib, nilotinib, and dasatinib can inhibit multiple growth factor (MGF)-induced proliferation and migration; (3) study the expression, regulation, and contribution of SFKs in PAH; (4) analyze the influence of dasatinib, imatinib, and nilotinib on Src tyrosine kinase activity; and (5) compare the reverse remodeling potency exerted by dasatinib, nilotinib, and imatinib in experimental PH.
Materials and Methods

McT Treatment, inhibitor Treatment, and Hemodynamic Measurements
Local ethics committees approved all animal experiments. Rats were injected with 60 mg/kg monocrotaline (MCT) subcutaneously. Twenty-one days after a single MCT injection, rats were randomized to receive daily dasatinib (5 mg/kg per body weight [bw] or 15 mg/kg per bw), nilotinib (30 mg/kg per bw), imatinib (100 mg/kg per bw), or placebo (2% Methocell) orally by gavage for 14 days. After 5 weeks, hemodynamics, cardiac output, and right ventricular (RV) hypertrophy were assessed (detailed protocol is available in the online-only Data Supplement).
Assessment of Vascular remodeling and Proliferation in situ
Paraffin-embedded lung sections were double stained with -smooth muscle actin and von Willebrand factor antibodies for assessing the degree of muscularization of peripheral pulmonary arteries. In addition, lung sections were stained for Elastin-Nuclear Fast Red to assess medial wall thickness. Vessels were detected by staining for von Willebrand factor, proliferation by staining for proliferating cell nuclear antigen (PCNA), and apoptosis by staining with an in situ cell death detection kit.
cell culture
Human PASMCs (hPASMCs) were obtained from Lonza. Primary rat PASMCs were isolated from control and MCT-induced PH (MCT-PH) rats by explant method.
Proliferation Assays
Influence of dasatinib, nilotinib, and imatinib on PDGF-BB-induced or MGF-induced (5% fetal calf serum, PDGF-BB 30 ng/mL, FGF 2 ng/mL, EGF 0.5 ng/mL, insulin 0.5 g/mL) PASMC proliferation was assessed using a bromodeoxyuridine (BrdU) incorporation assay, where the rates of DNA synthesis were used as a marker of cellular proliferation. The concentrations of the inhibitors were selected on the basis of previous publications.
chemotaxis Assays
Influence of dasatinib, nilotinib, and imatinib on PDGF-BB-or MGFinduced PASMC chemotaxis was assayed using a modified Boyden chemotaxis chamber. Chemotaxis was quantified by counting the number of cells on the lower surface of the filter in each well using a grid containing 100 nonoverlapping fields. immunocytochemistry hPASMCs were grown on chamber slides and were fixed immediately in acetone and methanol. The fixed cells were incubated overnight at 4C with anti-Lyn, -Hck, -Fyn, -Yes, and -c-Src. Fluorescence microscopy was performed after incubation with fluorescein isothiocyanate-conjugated secondary IgG antibodies, followed by 4,6-diamidino-2-phenylindole staining.
Western Blotting Analysis
hPASMCs were lysed in radioimmunoprecipitation assay lysis buffer (Sigma) containing protease and phosphatase inhibitors (Roche), and the lysates were subjected to Western blots.
real-Time reverse-Transcription Polymerase chain reaction
Total RNA was reverse transcribed with ImProm-II Reverse Transcription System, followed by real-time polymerase chain reaction analysis of human and rat Lck, Hck, Fyn, Blk, Lyn, Fgr, Yes, c-Src, and porphobilinogen deaminase using the primers described in Table IA As shown in Figure 1A through 1C, 1 to 3 mol/L imatinib and 0.1 to 0.3 mol/L nilotinib were required to block p-PDGFR. Similarly, at these concentrations, both imatinib and nilotinib markedly inhibited Akt and STAT3 phosphorylation. On the other hand, dasatinib completely blocked PDGF-BB-stimulated p-PDGFR at 0.03 mol/L. Importantly, this concentration of dasatinib also potently inhibited PDGFinduced Akt and STAT3 phosphorylation. 
influence of imatinib, Nilotinib, and dasatinib on PdGF-induced src Tyrosine Kinase Activity in hPAsMcs
Because Src activity was shown to be elevated by stimulation of quiescent fibroblasts with PDGF, 18 we studied the timedependent activation of Src tyrosine kinase activity/phosphorylation by PDGF-BB stimulation in hPASMCs. Accordingly, PDGF-BB markedly increased Src phosphorylation (p-Src) in a time-dependent manner, increasing in as early as 5 minutes, and sustained until 30 minutes ( Figure 2C ).
Furthermore, we determined whether dasatinib, nilotinib, and imatinib could inhibit PDGF-BB-induced p-Src. Importantly, all 3 inhibitors blocked Src tyrosine phosphorylation in response to PDGF-BB in a concentration-dependent manner ( Figure 2D-2F ). However, compared with imatinib and nilotinib, maximal reduction of p-Src was achieved even with the lowest concentration of dasatinib (0.03 mol/L) in PDGF-BB-stimulated PASMCs after 30 minutes ( Figure 2F ).
inhibition of PdGF-induced hPAsMc Proliferation by imatinib, Nilotinib, and dasatinib
Given the potent inhibitory potential of dasatinib, imatinib, and nilotinib on p-PDGFR and PDGF-BB-activated downstream signaling molecules, we studied the effects of each inhibitor on PDGF-BB-induced PASMC proliferation. PDGF-BB stimulation caused an ≈3-fold increase in BrdU uptake compared with nonstimulated cells. As shown in Figure 3A and 3B, imatinib and nilotinib at 3 to 10 mol/L effectively inhibited PDGF-BB-induced PASMC BrdU uptake. However, dasatinib at 0.03 to 0.1 mol/L was sufficient to achieve the similar inhibitory effects on PDGF-BB-induced PASMC BrdU uptake, suggesting a 100-fold higher potency of dasatinib ( Figure 3C ). We further analyzed the effects of dasatinib, imatinib, and nilotinib on PDGF-BB-induced change in cell cycle regulators. Importantly, all 3 inhibitors at the above-mentioned concentrations reversed the PDGF-BB-induced downregulation of the cyclin-dependent kinase inhibitor p27 and induction of cyclin D1. However, there was no effect of PDGF-BB and the above inhibitors on the regulation of other cyclin-dependent kinase inhibitors such as p21 ( Figure 3D-3F) .
imatinib, Nilotinib, and dasatinib Potently inhibit PdGF-induced chemotaxis of hPAsMcs
To study the influence of dasatinib, nilotinib, and imatinib on PDGF-BB-induced chemotaxis of hPASMCs, we used a modified Boyden chamber assay. PDGF-BB stimulation increased PASMC chemotaxis ≈3 times the baseline value of nonstimulated cells ( 
dasatinib But Not imatinib or Nilotinib inhibited MGF-induced Proliferation in hPAsMcs
Further considering the putative involvement of several growth factors in the abnormal phenotype of hPASMCs and thus in the pathogenesis of PAH, we studied the inhibition of MGF-activated signaling in hPASMCs by different concentrations of imatinib, nilotinib, and dasatinib. MGF stimulation significantly increased p-PDGFR, Akt, and STAT3. Dasatinib reduced this effect in a greater manner compared with imatinib and nilotinib ( Figure IIA -IIC in the onlineonly Data Supplement). Therefore, we also compared the antiproliferative potential of imatinib, nilotinib, and dasatinib on MGF-induced hPASMC BrdU uptake. MGF induced an ≈6-fold increase in BrdU uptake compared with nonstimulated cells. Treatment with various concentrations of imatinib and nilotinib did not significantly influence BrdU uptake induced by MGF ( Figure 4A and 4B) . In contrast, dasatinib effectively inhibited MGF-stimulated hPASMC cellular uptake of BrdU, and a complete inhibition was achieved at 3 mol/L dasatinib ( Figure 4C ).
In addition, we studied the effects of imatinib, nilotinib, or dasatinib on MGF-induced hPASMC chemotaxis. Similar to PDGF-BB, MGF increased hPASMC chemotaxis ≈3-fold compared with nonstimulated cells (Figure 4D-4F ). All 3 compounds, imatinib, nilotinib, and dasatinib, decreased MGFinduced chemotaxis in a concentration-dependent manner, but dasatinib appeared to be the most effective compound.
dasatinib But Not imatinib or Nilotinib inhibited MGF-induced p-src in hPAsMcs
Because SFKs interact with, and participate in signaling from, several RTKs in multiple ways, including DNA synthesis, 16 we presumed that the differential effects exerted by imatinib, nilotinib, or dasatinib on MGF-induced PASMC proliferation may involve the regulation of SFKs. Hence, we studied the effects of various growth factors present in our MGF cocktail, namely EGF, basic FGF, and IGF-1, on p-Src after 15 and 30 minutes. Among the 3, IGF-1 and EGF substantially increased p-Src ( Figure 5A and 5B), which was abolished by dasatinib ( Figure  IIIA and IIIB in the online-only Data Supplement). On the Figure 1 . Effect of imatinib, nilotinib, or dasatinib on platelet-derived growth factor (PDGF)-stimulated PDGF receptor, Akt, and signal transducer and activator of transcription 3 (STAT3) phosphorylation in human pulmonary arterial smooth muscle cells (PASMCs). A to C, Human PASMCs (hPASMCs) were preincubated with indicated concentrations of imatinib, nilotinib, dasatinib, or dimethyl sulfoxide (DMSO) (-) and then treated with PDGF-BB. Cell lysates were analyzed by Western blotting with antibodies to PDGF receptor phosphorylation (p-PDGFR), PDGFR, p-Akt, Akt, p-STAT3, STAT3, and GAPDH; n4.
other hand, basic FGF did not show any effect on p-Src ( Figure  5C ). In agreement with these results, even MGF, consisting of all these growth factors, caused robust p-Src ( Figure 5D -5F). Treatment with dasatinib at 0.3 to 3 mol/L completely abolished this effect. On the contrary, both imatinib and nilotinib had only weak or no influence on MGF-induced p-Src.
To further elucidate the involvement of Src in MGFinduced PASMC proliferation, we used 2 SFK blockers, 
imatinib, Nilotinib, and dasatinib influence Hemodynamics and rV Hypertrophy in McTinduced PAH at different concentrations
To assess and compare the therapeutic potential of imatinib, nilotinib, and dasatinib in MCT-PH, rats were treated 3 weeks after MCT injection with the respective RTK inhibitors or placebo for 14 days. Placebo-treated MCT-PH rats exhibited a significant increase in RV systolic pressure on day 35 (83.66.4 mm Hg) compared with control rats (29.11.4 mm Hg; Figure 6A ). Furthermore, compared with control animals (38.55.3 mL/min per 100 g bw), the cardiac index was decreased on day 35 (29.63.1 mL/min per 100 g bw; Figure 6B ). No significant changes in systemic vascular resistance index occurred ( Figure VA in the online-only Data Supplement). Importantly, dasatinib (both 5 and 15 mg/kg per bw), nilotinib (30 mg/kg per bw), and imatinib (100 mg/kg per bw) treatment (day 21-35) resulted in a remarkable reduction Figure 3 . Effects of imatinib, nilotinib, or dasatinib on platelet-derived growth factor (PDGF)-induced proliferation and cell cycle regulators in human pulmonary arterial smooth muscle cells (PASMCs). A to C, Human PASMCs (hPASMCs) were stimulated with PDGF-BB in the presence of various concentrations of imatinib, nilotinib, dasatinib, or dimethyl sulfoxide (DMSO) (-) and measured for the changes in proliferation by bromodeoxyuridine (BrdU) incorporation. All data are expressed as fold increase of the nonstimulated group and represent meansSEM; n4. *P0.05 vs nonstimulated; †P0.05 vs PDGF-treated group. D to F, Effects on cell cycle regulators were analyzed by Western blotting with antibodies to cyclin D1, p27, and p21; n4.
of RV systolic pressure to 63.14.6, 38.42.3, 56.05.6, and 47.94.4 mm Hg, respectively ( Figure 6A ). In the dasatinib (15 mg/kg per bw) group, cardiac index significantly increased compared with all other treatment groups ( Figure  6B ). Systemic arterial pressure increased whereas systemic vascular resistance index did not change in the dasatinibtreated group compared with placebo-treated MCT-PH rats ( Figure 
Nilotinib and dasatinib Affect Vascular remodeling
We quantitatively assessed the degree of muscularization of small pulmonary arteries (diameter 20-70 m). In controls, the majority of vessels of this size were nonmuscularized (79.54.5%), with a small percentage of partially muscularized arteries (14.04.0%) and an even smaller number of fully muscularized arteries (6.50.5%). In contrast, the percentage of nonmuscularized arteries decreased to 5.73.6%, and the percentage of partially and fully muscularized arteries increased to 43.03.9% and 51.36.1%, respectively, in placebo-treated MCT-PH rat lungs ( Figure 6D and 6E). Dasatinib treatment (15 mg/kg per day) led to a remarkable reduction in fully muscularized arteries to 17.53.1%, accompanied by a significant increase in partially muscularized arteries to 53.45.9% and nonmuscularized pulmonary arteries to 31.34.4% ( Figure 6D and 6E). In addition, nilotinib treatment also reduced the percentage of fully muscularized arteries compared with placebotreated MCT-PH rat lungs ( Figure 6D and 6E).
dasatinib exerts Antiproliferative and Proapoptotic effects in Vitro and in Vivo
The antiproliferative effects of dasatinib and nilotinib were assessed in vivo by immunostaining for PCNA. In MCTinjected rats, PCNA labeling showed proliferation of vascular cells in distal pulmonary arteries compared with controls ( Figure 6E 
discussion
Our data demonstrate that nilotinib and dasatinib are potent inhibitors of PDGF-BB-stimulated cellular responses, ie, proliferation and migration of PASMCs, comparable with imatinib. On the other hand, dasatinib exerts differential effect on MGF-induced PASMC proliferation compared with imatinib and nilotinib. Using selective inhibitors, we demonstrate that this differential effect of dasatinib is via additional inhibition of SFKs. The crucial role of SFKs in PASMC hyperplasia was further supported by an increased p-Src state in PASMCs isolated from experimental models of PAH. Consistent with these findings, dasatinib treatment reduced vascular cell proliferation in situ and reversed MCT-and HOX-induced PH, and this effect was more pronounced and achieved with a lower concentration compared with nilotinib and imatinib ( Figure 6 and Figure VII in the online-only Data Supplement). Taken together, these results suggest that dysregulated SFKs contribute to pulmonary vessel remodeling, and represent an additional therapeutic target in PAH.
Vascular remodeling due to PASMC proliferation and migration is central to the development of PH.
2 PASMC proliferation requires the coordinated interaction of several growth factors, including PDGF, EGF, FGF, and others, that are released in an autocrine/paracrine manner and act as potent mitogens and chemoattractants for PASMCs. 11 In agreement with others, we have found that PDGF is overexpressed and promotes vascular remodeling in PAH. 4, 5 However, inhibition of PDGF-mediated cellular responses by imatinib in PASMCs requires micromolar concentrations. 9 In contrast, near-complete inhibition of PDGFR activation and PDGF-stimulated activities in PASMCs was observed with nanomolar concentration of nilotinib and dasatinib in the present study. Dasatinib and nilotinib effectively blocked PDGF-stimulated PDGFR tyrosine phosphorylation. Furthermore, nilotinib and dasatinib suppressed PDGF-BB-stimulated activation of Akt and STAT3 in PASMCs. Both nilotinib and dasatinib effectively inhibited PDGF-BB-stimulated PASMC migration and proliferation. Direct comparison of imatinib, nilotinib, and dasatinib in PASMCs indicates that nilotinib is ≈10-fold and dasatinib is ≈100-fold more potent than imatinib, suggesting dasatinib is a more potent inhibitor of PDGF signaling than imatinib and nilotinib. This observation is consistent with a recent study by Chen et al, 19 in which dasatinib was shown to be 67-fold more potent than imatinib in the inhibition of PDGFR activation in vascular smooth muscle cells.
Among the other RTKs (EGF, FGF, IGF) that are thought to contribute to the pathobiology of PAH, epidermal growth factor receptor blockade was shown to inhibit PASMC growth, induce apoptosis, and provide partial therapeutic efficacy in animal models of PH. 20, 21 In analogy, increased lung and circulating FGF2 levels have been reported in both experimental and human PAH. Knockdown of FGF2 in pulmonary arterial endothelial cells using small interfering RNA reduced PASMC growth. 22 In addition, IGF-1 was shown to stimulate PASMC proliferation. 23 Because activation of EGF, FGF, IGF, and insulin receptors was shown to contribute to PASMC proliferative responses, we studied the antiproliferative and antimigratory potential of imatinib, nilotinib, or dasatinib in the presence of MGFs.
All 3 inhibitors potently inhibited the MGF-induced migration of PASMCs. In contrary, neither imatinib nor nilotinib affected MGF-induced proliferation of PASMCs. However, dasatinib significantly reduced MGF-induced proliferation of PASMCs, suggesting that in addition to the well-documented role of PDGF, the proliferation of PASMCs is also driven by PDGFR-independent mechanisms. This finding can be explained by the potential of dasatinib to inhibit both PDGFR and SFKs. These data are in line with the studies in other vascular smooth muscle cell types. Dual inhibition of PDGFRβ and SFKs was shown to inhibit both proliferation and migration in coronary arterial smooth muscle cells, 24 and dasatinib was effective in inhibiting PDGF-stimulated aortic smooth muscle cell migration and proliferation. 19 The importance of SFKs in the inhibition of abnormal vascular smooth muscle cell activities can be underpinned by the fact that SFKs are the major cytosolic tyrosine kinases in vascular tissue 25 and represent a crucial proximal component of the signaling cascades activated by growth factor receptors. 16 We have observed that PDGF, a key player in the pathogenesis of PAH, potently stimulates Src signaling in hPASMCs. Moreover, activation of Src kinases was not only observed in vitro in PASMCs stimulated with MGF, but also in vivo in PASMCs isolated from an experimental model of PH. These findings suggest that SFKs may be a central hub for various growth factors including PDGF, EGF, FGF, and insulin, and suggest that Src activation is necessary for the stimulation of DNA synthesis. This observation is consistent with previous findings, where Src was shown to be necessary and sufficient for human airway smooth muscle cell proliferation and migration. 26 In this setting, it is noteworthy that treatment with dasatinib, but not imatinib and nilotinib, dose-dependently decreased MGF-induced p-Src/activation. Furthermore, the importance of Src for PASMC proliferation is underlined by the observation that the combination of specific inhibitors of SFKs, PP1 and PP2 with imatinib or nilotinib, efficiently reduced MGFinduced PASMC proliferation that was resistant to single imatinib or nilotinib treatment suggesting the generation of a dasatinib phenotype by this combination approach. Indeed, accumulating evidence has suggested a crucial role of SFKs in pulmonary vascular homeostasis. 27 A direct role of SFKs in the acute contractile response to HOX in small pulmonary arteries of rats has been suggested. 28 On the other hand, activation of c-Src by the serotonin 2B receptor induces p-PDGFR and activates cell cycle regulators such as cyclins D and E, thus leading to cell proliferation. 29 Because we have recently shown an upregulation of 5-hydroxytryptamine (serotonin) receptor 2B in PASMCs isolated from patients with PAH, 30 an active involvement of SFKs in PAH pathogenesis can be suggested. Furthermore, the interaction of c-Src with bone morphogenetic protein receptor type II C-terminus and the regulation of this interaction by bone morphogenetic protein ligands 27 strongly implicate SFKs in the pathophysiology of PAH.
Importantly, involvement of Src and PDGFR kinases in PASMC proliferation and migration is of direct clinical interest, because dual Src kinase and PDGFR inhibitor, dasatinib, was recently approved for the treatment of chronic myelogenous leukemia resistant to imatinib. 31 In our studies, assessment of the therapeutic potential of dasatinib (5 and 15 mg/kg bw) and nilotinib (30 mg/kg bw) in vivo demonstrated reversal of established MCT-and HOX-induced PH in rats and mice. Beneficial effects were observed in 2 different animal models of PH that address media hypertrophy along with the aspect of interspecies differences. For instance, studies have clearly demonstrated interspecies differences in the responses to stimuli capable of promoting PH. Nevertheless, it would be interesting to carry out similar studies in 2 additional models, namely pneumonectomy+MCT and SUGEN+HOX, characterized by neointima formation. 32, 33 Importantly, headto-head comparison of imatinib, nilotinib, and dasatinib demonstrated a stronger reverse remodeling potential of dasatinib compared with nilotinib and imatinib. The more pronounced antihypertensive effects of dasatinib achieved even with lower concentrations of the inhibitor are most likely explained by its additional ability to inhibit MGF-induced Src activation. Similar preclinical efficacy of dasatinib has also been demonstrated in dermal fibrosis and systemic sclerosis. 34 To our knowledge, this is the first study to describe the reverse remodeling potential of dasatinib in PH.
Despite our finding that dasatinib was more efficient in reducing pulmonary vascular remodeling and experimental PH than other tyrosine kinase inhibitors, current observations indicate that chronic treatment with dasatinib for chronic myeloid leukemia was associated with the onset of severe PAH in humans. [35] [36] [37] [38] [39] In fact, the association is strong enough that the Food and Drug Administration has relabeled dasatinib with a specific warning about the risk of PAH with its use. This effect, however, appears to be mechanistically different, because PAH occurred in conjunction with pleural effusions and appeared to be reversible after termination of dasatinib. Therefore, it is assumed that the pathophysiological mechanism leading to an increase of pulmonary vascular resistance by dasatinib in humans differs from the vascular alterations typically seen in PAH. These effects appear to be functional whereas the dasatinib properties described in the present study are due to antiproliferative effects. Although the mechanism of PAH induction in humans remains elusive, it is likely to be related to off-kinase inhibition which may affect pulmonary vascular wall integrity, possibly leading to (peri) vascular edema and subsequent pulmonary vascular resistance increase. 33 Our data indicate that the additional effect of dasatinib on experimental PH is due to the additional targeting of SFKs by this compound, because the addition of Src inhibitors to imatinib was able to mimic the full dasatinib effect in vitro. Although our data are intriguing, it must be emphasized that carefully controlled clinical trials are absolutely necessary before extrapolating the animal model studies to the complex pathophysiology of human PAH. Effective, approved therapies for PAH exist, and especially because dasatinib has a Food and Drug Administration-labeled warning regarding the possibility for PAH, compassionate use or similar off-label use of dasatinib is inappropriate.
In summary, our study explores the regulation and previously undefined role of SFKs in the pathogenesis of PAH. The present study suggests that a dual inhibitor of PDGFR and SFKs potently interferes with motogenic and mitogenic responses of PASMCs in vitro and in vivo and thus, may represent a novel therapeutic approach to the treatment of PAH.
